Swissmedic approves bivalent Covid-19 booster vaccine from Pfizer

14. Oktober 2022 – Swissmedic has temporarily authorised Comirnaty Bivalent Original / Omicron BA.1 (tozinameran / riltozinameran), containing messenger ribonucleic acid (mRNA) against two coronavirus variants. A booster vaccination with this vaccine showed higher antibody concentrations against Omicron variant BA.1 than one with original Comirnaty in studies. The side effects profile in the study was similar to that of the original vaccine.

For more information, see here.